Closing the gap: cardiovascular disease in women.

IF 2.9 4区医学 Q1 OBSTETRICS & GYNECOLOGY

Climacteric Pub Date : 2024-02-01 Epub Date: 2024-01-15 DOI:10.1080/13697137.2023.2281935

M Nathani, B Vogel, R Mehran

引用次数: 0

Abstract

Cardiovascular disease (CVD) in women remains understudied, under-recognized, underdiagnosed and undertreated. Initiatives such as the Lancet Women and Cardiovascular Disease Commission help to identify sex and gender-related gaps in research, care and outcomes and to guide next steps in addressing them. This article highlights important aspects of the Lancet Commission report and expands on the evidence and proposed strategies for reducing the global burden of CVD in women. Furthermore, the article explores the benefits of cross-specialty collaborations for the treatment and prevention of CVD in women and discusses the impact of gender-related disparities in academic cardiology.

查看原文本刊更多论文

缩小差距：女性心血管疾病。

女性心血管疾病（CVD）仍然研究不足、认识不足、诊断不足和治疗不足。柳叶刀妇女与心血管疾病委员会等倡议有助于确定在研究、护理和结果方面与性别相关的差距，并为下一步解决这些问题提供指导。本文重点介绍了柳叶刀委员会报告的重要内容，并阐述了减少全球女性心血管疾病负担的证据和建议策略。此外，文章还探讨了跨专业合作对治疗和预防女性心血管疾病的益处，并讨论了与性别相关的差距对心脏病学学术界的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Climacteric 医学-妇产科学

CiteScore

1.70

自引率

7.10%

发文量

审稿时长

1 months

期刊介绍： Climacteric is the official journal of the International Menopause Society (IMS). As an international peer-reviewed journal it publishes original research and reviews of all aspects of aging in women. Climacteric was founded by the IMS in 1998 and today has become a leading journal in the publication of peer-reviewed papers on the menopause, climacteric and mid-life health. Topics covered include endocrine changes, symptoms attributed to the menopause and their treatment, hormone replacement and alternative therapies, lifestyles, and the counselling and education of peri- and postmenopausal women. Climacteric, published bimonthly, also features regular invited reviews, editorials and commentaries on recent developments. The editorial review board of Climacteric includes leading scientific and clinical experts in the field of midlife medicine and research and is headed by its Editor-in-Chief, Professor Rod Baber of Australia. He and his team of Associate Editors act independently to set a clear editorial policy, co-ordinate peer review, and ensure a rapid response to submitted papers.